12,372 trials
Attention Deficit Hyperactivity Disorder
Primary: Swanson, Kotkin, Agler, M-Flynn and Pelham Combined Score (SKAMP CS) - Model-adjusted Average of All Post-dose Time Points Assessed During a Laboratory Classroom Test…
Attention Deficit Hyperactivity Disorder
Primary: Attention Deficit Hyperactivity Disorder Rating Scale Based on DSM-IV Criteria (ADHD-RS-IV) Total Score. — 24.1; 31.2 ADHD-RS-IV total score — p=0.05
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Number of Adverse Events (AEs) Per Infusion — 0.032 Adverse events per infusion
Epilepsy, Tonic-clonic
Primary: Percentage Participants With Treatment Emergent Adverse Events — 27.3 percentage of participants
Chronic Lymphocytic Leukemia
Primary: Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death…
Hypertriglyceridemia
Primary: Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides — -15.57; -21.78; 11.15 % (percent change from baseline) — p=<0.0001
Sickle Cell Anemia · Sickle Cell Disease · Malaria
Primary: Number of Malaria Episodes — 5; 7 malaria episodes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (%) - Week 26 — 8.2; 8.1; -1.1; -1.1 % of HbA1c — p=<0.0001
Schizophrenia
Primary: Participants With Treatment-Emergent Adverse Events (TEAE) — 306; 21; 22; 18 Participants
Hypoglycemia · Diabetes Mellitus, Type 1
Primary: Hypoglycemia Rescue: Intent-to-Treat Population — 74; 79 Participants
Plaque Psoriasis
Primary: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) — 18.3; 9.6 percentage of participants
Bleeding
Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II) — -20.71; -93.86; -32.70; -92.34 Percent change in anti-fXa activity — p=<0.0001
Plaque-type Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) 75 Response and Investigators' Global Assessment (IGA) Mod 2011 0 or 1 Response — 71.7; 86.7; 3.3; 53.3 Percentages of…
Generalized Anxiety Disorder (GAD)
Primary: Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Visit 7 (Day 42) — -9.01; -8.93 Score on scale
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Primary: Defervescence Rate Within 48 Hours After the Start of the Study Drug Administration — 75.0; 33.3 percentage of patients